533 related articles for article (PubMed ID: 28476781)
1. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
[TBL] [Abstract][Full Text] [Related]
2. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
3. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
4. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
5. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
6. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
7. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
[TBL] [Abstract][Full Text] [Related]
8. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
9. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy.
Maire F; Voitot H; Aubert A; Palazzo L; O'Toole D; Couvelard A; Levy P; Vidaud M; Sauvanet A; Ruszniewski P; Hammel P
Am J Gastroenterol; 2008 Nov; 103(11):2871-7. PubMed ID: 18775021
[TBL] [Abstract][Full Text] [Related]
11. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
[TBL] [Abstract][Full Text] [Related]
12. Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus.
Tanaka M
Digestion; 2014; 90(4):265-72. PubMed ID: 25591885
[TBL] [Abstract][Full Text] [Related]
13. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology, Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm.
Moris M; Raimondo M; Woodward TA; Skinner V; Arcidiacono PG; Petrone MC; De Angelis C; Manfrè S; Fusaroli P; Asbun H; Stauffer J; Wallace MB
Pancreas; 2016 Jul; 45(6):870-5. PubMed ID: 26646270
[TBL] [Abstract][Full Text] [Related]
15. The role of endoscopic ultrasound in the management of intraductal papillary mucinous neoplasms: a systematic update.
Smith LA; McKay CJ
Minerva Med; 2016 Dec; 107(6):370-380. PubMed ID: 27627636
[TBL] [Abstract][Full Text] [Related]
16. Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.
Kucera S; Centeno BA; Springett G; Malafa MP; Chen YA; Weber J; Klapman J
JOP; 2012 Jul; 13(4):409-13. PubMed ID: 22797397
[TBL] [Abstract][Full Text] [Related]
17. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
[TBL] [Abstract][Full Text] [Related]
20. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]